NASDAQ:AVIR
Atea Pharmaceuticals Inc Stock News
$3.38
+0.0100 (+0.297%)
At Close: Jun 27, 2024
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
07:00am, Wednesday, 29'th May 2024
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral t
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial
Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript
10:00pm, Tuesday, 14'th May 2024
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communi
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
07:00am, Monday, 29'th Apr 2024
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral thera
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nas
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
11:24pm, Wednesday, 28'th Feb 2024
Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
04:05pm, Wednesday, 28'th Feb 2024
Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
07:00am, Wednesday, 21'st Feb 2024
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
10:31am, Wednesday, 10'th Jan 2024
Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.
A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 03'rd Jan 2024
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
First Clinical Data for Coadministration of Bemnifosbuvir and Ruzasvir Show Combination Was Well Tolerated in a Phase 1 Study
Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript
06:51pm, Wednesday, 08'th Nov 2023
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jonae Barnes - SVP, IR & Corporate Communications Jean-Pierre Sommadossi - F
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
04:05pm, Wednesday, 08'th Nov 2023
P atient enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19; first interim analysis expected 1Q24
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
07:00am, Wednesday, 08'th Nov 2023
BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral